AstraZeneca’s Soriot: New EU Legislation Will Accelerate Decline Of European Investment

Q1 Earnings Encouraging

 
• By Ayisha Sharma

AstraZeneca’s CEO criticized controversial draft EU legislation that could cut market protection periods for new therapies launched in the region during a Q1 earnings call that saw promising sales growth in line with full-year guidance.  

EU flags outside building
The Legislation Cuts Market Protection From Eights Years To Six • Source: Shutterstock

More from Earnings

More from Business